Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas

Daniel Schramek; Ataman Sendoel; Jeremy P. Segal; Slobodan Beronja; Evan Heller; Daniel Oristian; Boris Reva; Elaine Fuchs

doi:10.1126/science.1248627

Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas

Daniel Schramek, Ataman Sendoel, Jeremy P. Segal, Slobodan Beronja, Evan Heller, Daniel Oristian, Boris Reva, Elaine Fuchs

Research output: Contribution to journal › Article › peer-review

223 Scopus citations

Abstract

Mining modern genomics for cancer therapies is predicated on weeding out "bystander" alterations (nonconsequential mutations) and identifying "driver" mutations responsible for tumorigenesis and/or metastasis. We used a direct in vivo RNA interference (RNAi) strategy to screen for genes that upon repression predispose mice to squamous cell carcinomas (SCCs). Seven of our top hits - including Myh9, which encodes nonmuscle myosin IIa - have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. In human and mouse keratinocytes, myosin IIa's function is manifested not only in conventional actin-related processes but also in regulating posttranscriptional p53 stabilization. Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors.

Original language	English
Pages (from-to)	309-313
Number of pages	5
Journal	Science
Volume	343
Issue number	6168
DOIs	https://doi.org/10.1126/science.1248627
State	Published - 2014

Access to Document

10.1126/science.1248627

Cite this

@article{8235fb99735f431dba9ea6ea0bb71c78,

title = "Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas",

abstract = "Mining modern genomics for cancer therapies is predicated on weeding out {"}bystander{"} alterations (nonconsequential mutations) and identifying {"}driver{"} mutations responsible for tumorigenesis and/or metastasis. We used a direct in vivo RNA interference (RNAi) strategy to screen for genes that upon repression predispose mice to squamous cell carcinomas (SCCs). Seven of our top hits - including Myh9, which encodes nonmuscle myosin IIa - have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. In human and mouse keratinocytes, myosin IIa's function is manifested not only in conventional actin-related processes but also in regulating posttranscriptional p53 stabilization. Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors.",

author = "Daniel Schramek and Ataman Sendoel and Segal, {Jeremy P.} and Slobodan Beronja and Evan Heller and Daniel Oristian and Boris Reva and Elaine Fuchs",

year = "2014",

doi = "10.1126/science.1248627",

language = "English",

volume = "343",

pages = "309--313",

journal = "Science",

issn = "0036-8075",

publisher = "American Association for the Advancement of Science",

number = "6168",

}

TY - JOUR

T1 - Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas

AU - Schramek, Daniel

AU - Sendoel, Ataman

AU - Segal, Jeremy P.

AU - Beronja, Slobodan

AU - Heller, Evan

AU - Oristian, Daniel

AU - Reva, Boris

AU - Fuchs, Elaine

PY - 2014

Y1 - 2014

N2 - Mining modern genomics for cancer therapies is predicated on weeding out "bystander" alterations (nonconsequential mutations) and identifying "driver" mutations responsible for tumorigenesis and/or metastasis. We used a direct in vivo RNA interference (RNAi) strategy to screen for genes that upon repression predispose mice to squamous cell carcinomas (SCCs). Seven of our top hits - including Myh9, which encodes nonmuscle myosin IIa - have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. In human and mouse keratinocytes, myosin IIa's function is manifested not only in conventional actin-related processes but also in regulating posttranscriptional p53 stabilization. Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors.

AB - Mining modern genomics for cancer therapies is predicated on weeding out "bystander" alterations (nonconsequential mutations) and identifying "driver" mutations responsible for tumorigenesis and/or metastasis. We used a direct in vivo RNA interference (RNAi) strategy to screen for genes that upon repression predispose mice to squamous cell carcinomas (SCCs). Seven of our top hits - including Myh9, which encodes nonmuscle myosin IIa - have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. In human and mouse keratinocytes, myosin IIa's function is manifested not only in conventional actin-related processes but also in regulating posttranscriptional p53 stabilization. Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors.

UR - http://www.scopus.com/inward/record.url?scp=84892594373&partnerID=8YFLogxK

U2 - 10.1126/science.1248627

DO - 10.1126/science.1248627

M3 - Article

AN - SCOPUS:84892594373

SN - 0036-8075

VL - 343

SP - 309

EP - 313

JO - Science

JF - Science

IS - 6168

ER -

Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas

Abstract

Access to Document

Fingerprint

Cite this